SVB Securities

XOMA Corporation Announces Closing of Tender Offer

Retrieved on: 
Wednesday, April 3, 2024
SVB Securities, Health, XRA, Lazard, KNTE, Sale, Expiration, Gibson Dunn, Mergers and acquisitions

The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Tuesday, April 2, 2024 (the “Expiration Date”).

Key Points: 
  • The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Tuesday, April 2, 2024 (the “Expiration Date”).
  • As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived.
  • Immediately after the Expiration Date, XOMA irrevocably accepted for payment all shares validly tendered and not validly withdrawn and expects to promptly pay for such shares.
  • Following the closing of the tender offer, XOMA merged Kinnate with and into a subsidiary, XRA 1 Corp. (the “Merger”), and all shares of Kinnate common stock that had not been validly tendered were converted into the right to receive the Offer Price.

Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Stifel, EUR, GJB2, Euronext Growth, Patient, Code, Interim, Reserved, Sofinnova, Clinical trial, Commercial code, Person

The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.
  • This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months.
  • The capital increase enables the Company to finance its activities until the end of 2025.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

Nkarta Announces Pricing of $240 Million Underwritten Offering

Retrieved on: 
Monday, March 25, 2024
Janus, SVB Securities, Montgomery Street, Mizuho Securities, 3rd Floor, Telephone, SAN, Research, Sale, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Annual report, OrbiMed, Equity capital markets, NK, State Street

Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.
  • The offering is expected to close on or about March 27, 2024, subject to customary closing conditions.
  • All securities in the offering are to be issued and sold by Nkarta.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus describing the terms of the offering.

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

Retrieved on: 
Monday, March 25, 2024
SVB Securities, Telephone, Oppenheimer Holdings, Sale, Attention, Prospectus, Therapy, Nicollet Mall, State Street

WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.

Key Points: 
  • WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.
  • At closing, the aggregate gross proceeds of the offering to Aquestive, before deducting underwriting discounts and commissions and other offering expenses paid by Aquestive, were approximately $75.0 million.
  • Leerink Partners and Piper Sandler acted as joint bookrunning managers for the offering.
  • H.C. Wainwright & Co. and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as financial advisors to the Company.

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

Retrieved on: 
Wednesday, March 20, 2024
SVB Securities, Epilepsy, Anaphylaxis, Telephone, Patient, Adrenaline, Ageing, Oppenheimer Holdings, Sale, Public expenditure, Attention, Prospectus, Therapy, Nicollet Mall, State Street

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.

Key Points: 
  • WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.
  • The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million.
  • In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions.

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, March 19, 2024
SVB Securities, Epilepsy, Anaphylaxis, Form, Telephone, Patient, Ageing, Adrenaline, Oppenheimer Holdings, Sale, Public expenditure, Attention, Security (finance), Prospectus, Therapy, Nicollet Mall, State Street, Pharmaceutical industry

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Key Points: 
  • WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
  • In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.
  • All of the securities in the public offering are being offered by Aquestive.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Retrieved on: 
Tuesday, March 19, 2024
SVB Securities, BofA Securities, Madison Avenue, Form, Telephone, Patient, SAN, Sale, Attention, Cancer, Security (finance), Therapy, OrbiMed, Jefferies, IPSC, State Street, Jefferies Group

The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.

Key Points: 
  • The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.
  • The gross proceeds from the underwritten offering and private placement are expected to be approximately $100.0 million before deducting underwriting discounts and commissions and other offering expenses.
  • BofA Securities, Jefferies, and Leerink Partners are acting as the joint bookrunning managers for the underwritten offering.
  • A final prospectus supplement relating to and describing the terms of the underwritten offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.

Unicycive Announces $50 Million Private Placement

Retrieved on: 
Thursday, March 14, 2024
SVB Securities, Patient, Sale, Kidney disease, Therapy, Dialysis, LOS

The gross proceeds of the private placement are expected to be $50 million, before deducting placement agent fees and other expenses.

Key Points: 
  • The gross proceeds of the private placement are expected to be $50 million, before deducting placement agent fees and other expenses.
  • The private placement is expected to close on March 18, 2024, subject to the satisfaction of customary closing conditions.
  • Leerink Partners and Piper Sandler are acting as placement agents for the private placement.
  • “This financing provides strong validation of the best-in-class potential for our clinical development programs led by Oxylanthanum Carbonate (OLC).

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Retrieved on: 
Wednesday, March 13, 2024
SVB Securities, Stifel, Common stock, Novo Holdings A/S, Sale, Public expenditure, Prospectus, Therapy, Security (finance)

Lexeo sold 6,278,905 shares of its common stock (“Common Stock”) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), at a sale price equal to $15.13 per share.

Key Points: 
  • Lexeo sold 6,278,905 shares of its common stock (“Common Stock”) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), at a sale price equal to $15.13 per share.
  • Lexeo intends to use net proceeds from the financing to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes.
  • The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, are expected to fund operating and capital expenditures into 2027.
  • Any offering of the shares sold in the private placement under the Resale Registration Statement will only be made by means of a prospectus.

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

Retrieved on: 
Monday, April 1, 2024
Health, Neurology, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, SVB Securities, Bankruptcy, Neurotoxin, Multiple sclerosis, Patient, King & Spalding, Merz, Sale, Perella Weinberg Partners, LLP, Security (finance), United States bankruptcy court, Morgan Stanley, Ernst & Young, DSM-IV codes, Therapy, Acorda Therapeutics

Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.
  • Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, headquartered in Frankfurt am Main, Germany.
  • The decision to file for Chapter 11 protection follows a lengthy strategic review during which the Company explored a wide range of strategic options.
  • Upon court approval, Acorda expects to minimize the impact of the bankruptcy process on its employees, customers, patients, and other key stakeholders.